INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2008

Short-term metformin administration slightly reduced peak aerobic capacity and exercise duration in healthy individuals.

Seventeen healthy adults completed a double-blind, placebo-controlled crossover study evaluating the effects of 7-9 days of metformin (final dose 2000 mg/d) on maximal aerobic capacity compared to placebo. Metformin significantly reduced VO2 peak (-2.7%), peak heart rate (-2.0%), peak ventilation (-6.2%), peak respiratory exchange ratio (-3.0%), and exercise duration (-4.1%) (all p<0.05). Metformin had no effect on rating of perceived exertion or ventilatory breakpoint, and correlations between the reduction in VO2 peak and other outcomes were weak and not significant.

Study type
Double-blind, placebo-controlled, crossover trial
Who was studied
17 healthy, normal-weight men (n=11) and women (n=6)
What was measured
Peak aerobic capacity (VO2 peak, HR, VE, RER, RPE, exercise duration)

THE PAPER

Impact of metformin on peak aerobic capacity.

Braun B, Eze P, Stephens BR, Hagobian TA, Sharoff CG, Chipkin SR, Goldstein B. Appl Physiol Nutr Metab, 2008.

PubMed 18347654 ↗DOI 10.1139/h07-144 ↗

Diabetes & blood sugarOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.